For the year ended December 31, 2024, NRx Pharmaceuticals reduced its loss from operations by approximately $9.3 million, or 33.5%, to $18.5 million, and $27.8 million for the year ended December ...

NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a market capitalization of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

BTIG Research assumed coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Utilities, Telecoms and Consumer Services ...

As of April 2, 2025, the average one-year price target for NRx Pharmaceuticals is $32.30/share. The forecasts range from a low of $19.19 to a high of $47.25. The average price target represents an ...